Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294874 | 1.00 | IDO1 (0.43) | IDO1MEN1KMT2APOLBMAPT | |
| SCHEMBL10569475 | 0.88 | MAPT (0.45) | IDO1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL8716890 | 0.88 | RAB9A (0.47) | IDO1MAPTALDH1A1RAB9AHTT | |
| SCHEMBL5481199 | 0.88 | RAB9A (0.49) | IDO1KMT2AMAPTHTR2ARAB9A | |
| SCHEMBL9050930 | 0.86 | MEN1 (0.43) | IDO1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4438089 | 0.86 | GAA (0.53) | MEN1KMT2AMAPTALDH1A1HTR2A | |
| SCHEMBL7278760 | 0.86 | GAA (0.53) | MEN1KMT2AMAPTALDH1A1HTR2A | |
| SCHEMBL7382040 | 0.85 | MAPT (0.48) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL1413274 | 0.82 | FABP7 (0.44) | IDO1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5484162 | 0.81 | ALDH1A1 (0.49) | IDO1MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592476-B2 | Process for producing enantiopure β-amino acid derivatives, and enantiopure β-amino acid derivatives | SOLVAY S.A. (BE) | 2009-09-22 | — | — | US | disclosed |
| US-20060211097-A1 | Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives | SOLVAY S.A. (BE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211097-A1 | Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives | LPL, CEL, IL4I1 | IDO1 603/4885MEN1 4598/4885KMT2A 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.